{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:27:40Z","timestamp":1766820460991,"version":"3.46.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10072-025-08422-1","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T06:14:00Z","timestamp":1759126440000},"page":"6479-6489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Polyradiculoneuropathies associated with immune checkpoint inhibitors: are we facing a new nosological entity?"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-3912","authenticated-orcid":false,"given":"Michele","family":"Trimboli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Cataldina","family":"Iusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cuc\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Tozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiore","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"8422_CR1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:1845\u20131855","journal-title":"N Engl J Med"},{"key":"8422_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A et al (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600\u20131609","journal-title":"JAMA"},{"key":"8422_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos A (2016) Development of immuno-oncology drugs: from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15:235\u2013247","journal-title":"Nat Rev Drug Discov"},{"key":"8422_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384","journal-title":"Lancet Oncol"},{"key":"8422_CR5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"8422_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for Immuno-therapy of cancer (SITC) toxicity management working group. J Immunother Cancer 5:95","journal-title":"J Immunother Cancer"},{"key":"8422_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120089","volume":"432","author":"E Khan","year":"2022","unstructured":"Khan E, Shrestha AK, Elkhooly M et al (2022) CNS and PNS manifestation in immune checkpoint inhibitors: a systematic review. J Neurol Sci 432:120089","journal-title":"J Neurol Sci"},{"key":"8422_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CND.0000000000000193","volume":"19","author":"S Supakornnumporn","year":"2017","unstructured":"Supakornnumporn S, Katirji B (2017) Guillain-Barre \u0301 syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis 19:80\u201383","journal-title":"J Clin Neuromuscul Dis"},{"key":"8422_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","volume":"45","author":"Y Gu","year":"2017","unstructured":"Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G (2017) Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 45:14\u201317","journal-title":"J Clin Neurosci"},{"key":"8422_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CJI.0000000000000172","volume":"40","author":"PT Diamantopoulos","year":"2017","unstructured":"Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H (2017) Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother 40:221\u2013223","journal-title":"J Immunother"},{"key":"8422_CR11","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1002\/mus.25672","volume":"56","author":"M Sep\u00f9lveda","year":"2017","unstructured":"Sep\u00f9lveda M, Martinez-Hernandez E, Gaba L et al (2017) Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve 56:E162\u2013E167","journal-title":"Muscle Nerve"},{"key":"8422_CR12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216\u20131222","journal-title":"JAMA Neurol"},{"key":"8422_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138","journal-title":"Eur J Cancer"},{"key":"8422_CR14","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"366","author":"RA Hughes","year":"2005","unstructured":"Hughes RA, Cornblath DR (2005) Guillain-Barr\u00e9 syndrome. Lancet 366:1653\u20131666","journal-title":"Lancet"},{"key":"8422_CR15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1055\/s-2003-39969","volume":"128","author":"H Koller","year":"2003","unstructured":"Koller H, Kieseier BC, Jander S, Hartung HP (2003) Acute and chronic inflammatory neuropathies: diagnosis. Dtsch Med Wochenschr 128:1357\u20131360","journal-title":"Dtsch Med Wochenschr"},{"key":"8422_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA Van Doorn","year":"2008","unstructured":"Van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barre \u0301 syndrome. Lancet Neurol 7:939\u2013950","journal-title":"Lancet Neurol"},{"key":"8422_CR17","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury AK, Cornblath DR (1990) Assessment of current diag- nostic criteria for Guillain-Barre \u0301 syndrome. Ann Neurol 27:S21\u2013S24","journal-title":"Ann Neurol"},{"key":"8422_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000052111","volume":"45","author":"PA Van Doorn","year":"2001","unstructured":"Van der Meche \u0301 FG, Van Doorn PA, Meulstee J, Jennekens FG (2001) Diagnostic and classification criteria for the Guillain- Barre \u0301 syndrome. Eur Neurol 45:133\u2013139","journal-title":"Eur Neurol"},{"key":"8422_CR19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.41.5.617","volume":"41","author":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)","year":"1991","unstructured":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) (1991) Report from an ad hoc subcommittee of the American academy of neurology AIDS task force. Neurology 41:617\u2013618","journal-title":"Neurology"},{"key":"8422_CR20","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, Van Doorn PA, Hadden RDM et al (2021) European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force\u2014second revision. Eur J Neurol 28:3556\u20133583","journal-title":"Eur J Neurol"},{"key":"8422_CR21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/jnnp.54.11.957","volume":"54","author":"RP van der Kleyweg","year":"1991","unstructured":"van der Kleyweg RP, Meche \u0301 FG (1991) Treatment related fluctuations in Guillain-Barre \u0301 syndrome after high-dose Immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 54:957\u2013960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8422_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-0404.1988.tb05909.x","volume":"77","author":"PO Osterman","year":"1988","unstructured":"Osterman PO, Fagius J, Safwenberg J, Wikstrom B (1988) Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand 77:273\u2013277","journal-title":"Acta Neurol Scand"},{"key":"8422_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/archneur.1988.00520270096026","volume":"45","author":"AE Ropper","year":"1988","unstructured":"Ropper AE, Albert JW, Addison R (1988) Limited relapse in Guillain-Barre \u0301 syndrome after plasma exchange. Arch Neurol 45:314 \u2013\u2009315","journal-title":"Arch Neurol"},{"key":"8422_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1212\/01.wnl.0000167549.09664.b8","volume":"65","author":"L Ruts","year":"2005","unstructured":"Ruts L, van Koningsveld R, van Doorn PA (2005) Distinguishing acute-onset CIDP from Guillain-Barr\u00e9 syndrome with treatment related fluctuations. Neurology 65:138\u2013140","journal-title":"Neurology"},{"key":"8422_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1212\/WNL.58.6.979","volume":"58","author":"K Mori","year":"2002","unstructured":"Mori K, Hattori N, Sugiura M et al (2002) Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 58:979\u2013982","journal-title":"Neurology"},{"key":"8422_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00415-003-1096-y","volume":"250","author":"M Odaka","year":"2003","unstructured":"Odaka M, Yuki N, Hirata K (2003) Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-barre \u0301 syndrome. J Neurol 250:913\u2013916","journal-title":"J Neurol"},{"key":"8422_CR27","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","volume":"74","author":"J Ruts","year":"2010","unstructured":"Ruts J, Drenthen J, Jacobs BC, van Doorn PA (2010) Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 74:1680\u20131686","journal-title":"Neurology"},{"key":"8422_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/mus.20297","volume":"31","author":"A Mygland","year":"2005","unstructured":"Mygland A, Monstad P, Vedeler C (2005) Onset and course of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 31:589\u2013593","journal-title":"Muscle Nerve"},{"key":"8422_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/jnnp.64.2.242","volume":"64","author":"LH Visser","year":"1998","unstructured":"Visser LH, van der Meche \u0301 FG, Meulstee J, van Doorn PA (1998) Risk factors for treatment related clinical fluctuations in Guillain-Barre \u0301 syndrome: Dutch Guillain-Barre \u0301 study group. J Neurol Neurosurg Psychiatry 64:242\u2013244","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8422_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R Van Koningsveld","year":"2007","unstructured":"Van Koningsveld R, Steyerberg EW, Hughes RAC et al (2007) Clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome. Lancet Neurol 6:589\u2013594","journal-title":"Lancet Neurol"},{"key":"8422_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2021.100324","volume":"22","author":"S Bolz","year":"2021","unstructured":"Bolz S, Ramakrishnan T, Fleischer M, Livingstone E, Stolte B, Thimm A, Kizina K, Ugurel S, Kleinschnitz C, Glas M, Zimmer L, Hagenacker T (2021) Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurolSci 22:100324","journal-title":"eNeurolSci"},{"key":"8422_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009262","volume":"96","author":"JH Chen","year":"2017","unstructured":"Chen JH, Lee KY, Hu CJ, Chung CC (2017) Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine 96:e9262","journal-title":"Medicine"},{"key":"8422_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"KL Reynolds","year":"2019","unstructured":"Reynolds KL, Guidon AC (2019) Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24:435\u2013443","journal-title":"Oncologist"},{"key":"8422_CR34","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jjco\/hyw090","volume":"46","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, Okune M, Inoue S, Sekine I, Tamaoka A, Fujimoto M (2016) Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report. Jpn J Clin Oncol 46:875\u2013878","journal-title":"Jpn J Clin Oncol"},{"key":"8422_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16:589\u2013593","journal-title":"Neuro Oncol"},{"key":"8422_CR36","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00415-020-10213-x","volume":"268","author":"K Okada","year":"2021","unstructured":"Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, Yamada S, Oki K, Nakahara J, Suzuki S (2021) Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol 268:680\u2013688","journal-title":"J Neurol"},{"key":"8422_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ (2013) A severe case of ipilimumab-induced guillain-barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36:77\u201378","journal-title":"J Immunother"},{"key":"8422_CR38","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/annonc\/mdr028","volume":"22","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof S, Neyns B (2011) Anti-CTLA-4 antibody-induced Guillain-Barr\u00e9 syndrome in a melanoma patient. Ann Oncol 22:991\u2013993","journal-title":"Ann Oncol"},{"key":"8422_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","volume":"13","author":"I Bot","year":"2013","unstructured":"Bot I, Blank CU, Boogerd W, Brandsma D (2013) Neurological immune-related adverse events of ipilimumab. Pract Neurol 13:278\u2013280","journal-title":"Pract Neurol"},{"key":"8422_CR40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.5692\/clinicalneurol.cn-001444","volume":"60","author":"R Hashimoto","year":"2020","unstructured":"Hashimoto R, Ueda T, Tsuji Y, Otsuka Y, Sekiguchi K, Matsumoto R (2020) Successful treatment of Guillain-Barr\u00e9 syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report. Rinsho Shinkeigaku 60:773\u2013777","journal-title":"Rinsho Shinkeigaku"},{"key":"8422_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230848","volume":"12","author":"J Pierrard","year":"2019","unstructured":"Pierrard J, Petit B, Lejeune S, Seront E (2019) Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barr\u00e9 syndrome occurring in a patient treated with nivolumab. BMJ Case Rep 12:e230848","journal-title":"BMJ Case Rep"},{"key":"8422_CR42","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1002\/mus.25663","volume":"56","author":"MD Yost","year":"2017","unstructured":"Yost MD, Chou CZ, Botha H, Block MS, Liewluck T (2017) Facial diplegia after pembrolizumab treatment. Muscle Nerve 56:E20\u2013E21","journal-title":"Muscle Nerve"},{"key":"8422_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.7735","volume":"33","author":"JJ Luke","year":"2015","unstructured":"Luke JJ, Lezcano C, Hodi FS, Murphy GF (2015) Antitumor granuloma formation by CD4\u2009+\u2009T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. J Clin Oncol 33:e32\u2013e35","journal-title":"J Clin Oncol"},{"key":"8422_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/jnnp-2017-316510","volume":"89","author":"Y Fukumoto","year":"2018","unstructured":"Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S (2018) Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry 89:435\u2013437","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8422_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0318-x","volume":"6","author":"L Cafuir","year":"2018","unstructured":"Cafuir L, Lawson D, Desai N, Kesner V, Voloschin A (2018) Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following ipilimumab. J Immunother Cancer 6:11","journal-title":"J Immunother Cancer"},{"key":"8422_CR46","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1002\/mus.25672","volume":"56","author":"M Sep\u00falveda","year":"2017","unstructured":"Sep\u00falveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falg\u00e0s N, Casanova-Molla J, Graus F (2017) Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve 56:E162\u2013E167","journal-title":"Muscle Nerve"},{"key":"8422_CR47","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M, O\u2019Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28:377\u2013385","journal-title":"Ann Oncol"},{"key":"8422_CR48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/CMR.0000000000000598","volume":"29","author":"N M\u00f6hn","year":"2019","unstructured":"M\u00f6hn N, S\u00fchs KW, Gingele S, Angela Y, Stangel M, Gutzmer R, Satzger I, Skripuletz T (2019) Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. Melanoma Res 29:435\u2013440","journal-title":"Melanoma Res"},{"key":"8422_CR49","volume":"10","author":"R Manam","year":"2018","unstructured":"Manam R, Martin JL, Gross JA, Chaudhary D, Chowdhary S, Espinosa PS, Santos ES (2018) Case reports of Pembrolizumab-induced acute inflammatory demyelinating polyneuropathy. Cureus 10:e3371","journal-title":"Cureus"},{"key":"8422_CR50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/CND.0000000000000230","volume":"20","author":"C Yuen","year":"2019","unstructured":"Yuen C, Kamson D, Soliven B, Kramer C, Goldenberg F, Rezania K (2019) Severe relapse of vaccine-induced Guillain-Barr\u00e9 syndrome after treatment with nivolumab. J Clin Neuromuscul Dis 20:194\u2013199","journal-title":"J Clin Neuromuscul Dis"},{"key":"8422_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3892\/mco.2020.2042","volume":"13","author":"C Han","year":"2020","unstructured":"Han C, Ma JA, Zhang Y, Jiang Y, Hu C, Wu Y (2020) Guillain-barre syndrome induced by pembrolizumab and sunitinib: a case report. Mol Clin Oncol 13:38\u201342","journal-title":"Mol Clin Oncol"},{"key":"8422_CR52","first-page":"5490707","volume":"2019","author":"N Gravbrot","year":"2019","unstructured":"Gravbrot N, Scherer K, Sundararajan S (2019) Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barr\u00e9 Syndrome: A Case Report and Review of the Literature. Case Rep Oncol Med. 2019:5490707","journal-title":"Case Rep Oncol Med."},{"key":"8422_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-229443","volume":"12","author":"CJ McNeill","year":"2019","unstructured":"McNeill CJ, Fehmi J, Gladwin J, Price C (2019) A rare case of Miller Fisher variant of Guillain-Barr\u00e9Syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Rep 12:e229443","journal-title":"BMJ Case Rep"},{"key":"8422_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577267","volume":"346","author":"C Maurice","year":"2020","unstructured":"Maurice C, Khoja L, Morgan E, Mason WP, Katzberg H, Pereira AM, Pereira A, Butler M (2020) Guillain-barr\u00e9 syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming. J Neuroimmunol 346:577267","journal-title":"J Neuroimmunol"},{"key":"8422_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100739","volume":"36","author":"BN Brzezinska","year":"2021","unstructured":"Brzezinska BN, Higgins RV, Rungruang B (2021) Guillain-barre syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: a case report and review of the literature. Gynecol Oncol Rep 36:100739","journal-title":"Gynecol Oncol Rep"},{"key":"8422_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030236","volume":"101","author":"H Moon","year":"2022","unstructured":"Moon H, Kim SG, Kim SK, Kim J, Lee SR, Moon YW (2022) A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: review of literature. Medicine (Baltimore) 101:e30236","journal-title":"Medicine (Baltimore)"},{"key":"8422_CR57","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/WNO.0000000000000755","volume":"39","author":"KE Green","year":"2019","unstructured":"Green KE, Levine AM, Ward JH, Kaufman DI (2019) GQ1b-seronegative miller fisher syndrome associated with pembrolizumab. J Neuroophthalmol 39:394\u2013396","journal-title":"J Neuroophthalmol"},{"key":"8422_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211037462","volume":"9","author":"T Oguri","year":"2021","unstructured":"Oguri T, Sasada S, Shimizu S, Shigematsu R, Tsuchiya Y, Ishioka K, Takahashi S, Oki K, Kimura Y, Seki R, Hirose S, Nakamura M (2021) A case of Guillain-Barr\u00e9 syndrome and Stevens-Johnson syndrome\/toxic epidermal necrosis overlap after pembrolizumab treatment. J Invest Med High Impact Case Rep 9:23247096211037462","journal-title":"J Invest Med High Impact Case Rep"},{"key":"8422_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620916358","volume":"8","author":"A Arora","year":"2020","unstructured":"Arora A, Shere A, Patel K, Gunawardhana N, LiFuentes E (2020) A rare case of autoimmune demyelinating polyneuropathy and hydrocephalus secondary to pembrolizumab. J Invest Med High Impact Case Rep 8:2324709620916358","journal-title":"J Invest Med High Impact Case Rep"},{"key":"8422_CR60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","volume":"6","author":"CA Garcia","year":"2018","unstructured":"Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer 6:83","journal-title":"J Immunother Cancer"},{"key":"8422_CR61","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/CJI.0000000000000285","volume":"42","author":"M Pomerantz","year":"2019","unstructured":"Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, Sohal R, Leibovitch J, Basnet A (2019) Nivolumab and ipilimumab-induced acute inflammatory demyelinating polyradiculoneuropathy: a case report. J Immunother 42:348\u2013349","journal-title":"J Immunother"},{"key":"8422_CR62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/CJI.0000000000000167","volume":"40","author":"W Kelly Wu","year":"2017","unstructured":"Kelly Wu W, Broman KK, Brownie ER, Kauffmann RM (2017) Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J Immunother 40:196\u2013199","journal-title":"J Immunother"},{"key":"8422_CR63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcrc.2021.05.020","volume":"65","author":"P Rajendram","year":"2021","unstructured":"Rajendram P, Torbic H, Duggal A, Campbell J, Hovden M, Dhawan V, Pastores SM, Gutierrez C (2021) Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: a multi-center case series. J Crit Care 65:126\u2013132","journal-title":"J Crit Care"},{"key":"8422_CR64","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00432-016-2191-7","volume":"142","author":"A Jacob","year":"2016","unstructured":"Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S (2016) A case of fatal Guillain-barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol 142:1869\u20131870","journal-title":"J Cancer Res Clin Oncol"},{"key":"8422_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1348304","volume":"15","author":"D Zhang","year":"2024","unstructured":"Zhang D, Wang Y, Zhou F (2024) Case report: resolution of Guillain-barr\u00e9 syndrome in a patient with dual primary tumors after treatment with rituximab. Front Neurol 15:1348304","journal-title":"Front Neurol"},{"key":"8422_CR66","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/CJI.0000000000000364","volume":"44","author":"JBE Janssen","year":"2021","unstructured":"Janssen JBE, Leow TYS, Herbschleb KH, Gijtenbeek JMM, Boers-Sonderen MJ, Gerritsen WR, Westdorp H (2021) Immune checkpoint inhibitor-related Guillain-Barr\u00e9 syndrome: a case series and review of the literature. J Immunother 44:276\u2013282","journal-title":"J Immunother"},{"key":"8422_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.908282","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Xu D, Liu Y, Cao Y, He J, Liao M (2022) Acupuncture treatment of Guillain-Barr\u00e9 syndrome after using immune checkpoint inhibitors: a case report. Front Neurol 13:908282","journal-title":"Front Neurol"},{"key":"8422_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1132692","volume":"14","author":"M Ding","year":"2023","unstructured":"Ding M, Deng C, Liu X, Jiang S, Gao Y, Fan D, Zhou Y, He J, Liu C (2023) Case report: ICIs-induced Guillain-Barr\u00e9 syndrome recovered from mycophenolate mofetil. Front Immunol 14:1132692","journal-title":"Front Immunol"},{"key":"8422_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.01.009","volume":"129","author":"A Indini","year":"2020","unstructured":"Indini A, Sessa M, Merelli B, Foresti C, Mandal\u00e0 M (2020) A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy. Eur J Cancer 129:1\u20133","journal-title":"Eur J Cancer"},{"key":"8422_CR70","volume":"16","author":"PO Idogun","year":"2024","unstructured":"Idogun PO, Hafez-Khayyata S, Ezekwudo D (2024) Immune checkpoint inhibitor-induced Guillain Barre syndrome: a single-institution case report and narrative review. Cureus 16:e61489","journal-title":"Cureus"},{"key":"8422_CR71","volume":"9","author":"C Rupareliya","year":"2017","unstructured":"Rupareliya C, Naqvi S, Jani VB (2017) Acute inflammatory demyelinating polyneuroradiculopathy with ipilimumab in metastatic melanoma: a case report and review of literature. Cureus 9:e1310","journal-title":"Cureus"},{"key":"8422_CR72","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.cllc.2019.11.001","volume":"21","author":"G Mazzaschi","year":"2020","unstructured":"Mazzaschi G, Bordi P, Fioretzaki R, Gnetti L, Milanese G, Tommasi C, Bersanelli M, Roti G, Scoditti U, Leonardi F, Quaini F, Tiseo M (2020) Nivolumab-induced Guillain-Barr\u00e9 syndrome coupled with remarkable disease response in a case of heavily pretreated lung adenocarcinoma. Clin Lung Cancer 21:e65\u2013e73","journal-title":"Clin Lung Cancer"},{"key":"8422_CR73","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/j.clgc.2018.11.022","volume":"17","author":"A Kyriazoglou","year":"2019","unstructured":"Kyriazoglou A, Liontos M, Papadopoulos C, Bilali A, Kostouros E, Pagoni S, Doumas K, Dimopoulos MA, Bamias A (2019) Guillain-barr\u00e9 syndrome related to nivolumab: case report of a patient with urothelial cancer and review of the literature. Clin Genitourin Cancer 17:e360\u2013e364","journal-title":"Clin Genitourin Cancer"},{"key":"8422_CR74","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1097\/MJT.0000000000000771","volume":"25","author":"B Thapa","year":"2018","unstructured":"Thapa B, Khalid S, Vakili R, Ui J, Misbah S (2018) Nivolumab-associated Guillain-barre syndrome in a patient with non-small-cell lung cancer. Am J Ther 25:e761\u2013e763","journal-title":"Am J Ther"},{"key":"8422_CR75","doi-asserted-by":"crossref","unstructured":"Patel RJ, Liu MA, Amaraneni A, Sindhu SK (2017) Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barr\u00e9 syndrome. BMJ Case Rep. 2017: bcr2017221318","DOI":"10.1136\/bcr-2017-221318"},{"key":"8422_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.547","author":"R Wilson","year":"2018","unstructured":"Wilson R, Menassa DA, Davies AJ et al (2018) Seronegative antibody-mediated neurology after immune checkpoint inhib itors. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.547","journal-title":"Ann Clin Transl Neurol"},{"key":"8422_CR77","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1941874418778957","volume":"8","author":"JJD Baird-Gunning","year":"2018","unstructured":"Baird-Gunning JJD, Weerasinghe D, Silsby M, Gawarikar Y, Carlino MS, Smith JL, Vucic S (2018) Miller fisher syndrome associated with immunotherapy for metastatic melanoma. Neurohospitalist 8:191\u2013193","journal-title":"Neurohospitalist"},{"key":"8422_CR78","doi-asserted-by":"publisher","DOI":"10.1159\/000504930","author":"S Muralikrishnan","year":"2020","unstructured":"Muralikrishnan S, Ronan LK, Coker S, Rauschkolb PK, Shirai K (2020) Treatment considerations for patients with unresectable metastatic melanoma who develop pembrolizumab-induced Guillain-Barr\u00e9 toxicity: a case report. Case Rep Oncol. https:\/\/doi.org\/10.1159\/000504930","journal-title":"Case Rep Oncol"},{"key":"8422_CR79","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s13760-021-01623-3","volume":"121","author":"K Nakamagoe","year":"2021","unstructured":"Nakamagoe K, Yamada T, Okune S, Moriwaki T, Tamaoka A (2021) Fisher syndrome as an immune -related adverse event after using pembrolizumab but not nivolumab. Acta Neurol Belg 121:1381\u20131382","journal-title":"Acta Neurol Belg"},{"key":"8422_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03177-8","volume":"23","author":"C Park","year":"2023","unstructured":"Park C, Kim KT (2023) Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for Hodgkin lymphoma: a case report. BMC Neurol 23:130","journal-title":"BMC Neurol"},{"key":"8422_CR81","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM et al (2021) Share European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task Force-Second revision. Eur J Neurol 28:3556\u20133583","journal-title":"Eur J Neurol"},{"key":"8422_CR82","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","volume":"30","author":"PA Van Doorn","year":"2023","unstructured":"Van Doorn PA, Van den Bergh PYK et al (2023) European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barre syndrome. Eur J Neurol 30:3646\u20133674","journal-title":"Eur J Neurol"},{"key":"8422_CR83","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D et al (2019) Varied phenotypes and management of immune checkpoint inhibitor\u2014a neuropathies. Neurology 93:e1093\u2013e1103","journal-title":"Neurology"},{"key":"8422_CR84","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10072-020-04604-1","volume":"42","author":"C Demichelis","year":"2021","unstructured":"Demichelis C, Balestra A, Lapucci C et al (2021) Neuromuscular complications following targeted therapy in cancer patients: beyond immune checkpoint inhibitors. Case reports and review of the literature. Neurol Sci 42:1405\u20131409","journal-title":"Neurol Sci"},{"key":"8422_CR85","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/CPJ.0000000000000331","volume":"7","author":"A Compter","year":"2017","unstructured":"Compter A, Boogerd W, van Thienen JV et al (2017) Acute polyneuropathy in a metastatic melanoma patient treated with Vemurafenib and Cobimetinib. Neurol Clin Pract 7:418\u2013420","journal-title":"Neurol Clin Pract"},{"key":"8422_CR86","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","volume":"20","author":"M O\u2019Hare","year":"2024","unstructured":"O\u2019Hare M, Guidon AC (2024) Peripheral nervous system immune-related adverse events due to checkpoint inhibition. Nat Rev Neurol 20:509\u2013525","journal-title":"Nat Rev Neurol"},{"key":"8422_CR87","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","volume":"74","author":"L Ruts","year":"2010","unstructured":"Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group (2010) Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 74:1680\u20131686","journal-title":"Neurology"},{"key":"8422_CR88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mus.26070","volume":"58","author":"NA Kolb","year":"2018","unstructured":"Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, Hehir M (2018) Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve 58:10\u201322","journal-title":"Muscle Nerve"},{"key":"8422_CR89","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","volume":"130","author":"X Chen","year":"2019","unstructured":"Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B (2019) Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol 130:1440\u20131445","journal-title":"Clin Neurophysiol"},{"key":"8422_CR90","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9800488","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang X, Zhao C (2021) Guillain-barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases. BioMed Res Int. https:\/\/doi.org\/10.1155\/2021\/9800488","journal-title":"BioMed Res Int"},{"key":"8422_CR91","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","volume":"375","author":"MF De Maleissye","year":"2016","unstructured":"De Maleissye MF, Nicolas G, Saiag P (2016) Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375:296\u2013297","journal-title":"N Engl J Med"},{"key":"8422_CR92","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jns.2018.04.028","volume":"390","author":"T Nukui","year":"2018","unstructured":"Nukui T, Nakayama Y, Yamamoto M, Taguchi Y, Dougu N, Konishi H, Hayashi T, Nakatsuji Y (2018) Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barr\u00e9 syndrome. J Neurol Sci 390:115\u2013116","journal-title":"J Neurol Sci"},{"key":"8422_CR93","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mus.24667","volume":"52","author":"M Anadani","year":"2015","unstructured":"Anadani M et al (2015) Acute-onset chronic inflammatory demyelinating polyneuropathy. An electrodiagnostic study. Muscle Nerve 52:900\u2013905","journal-title":"Muscle Nerve"},{"key":"8422_CR94","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00415-021-10404-0","volume":"268","author":"Q Fan","year":"2021","unstructured":"Fan Q, Hu Y, Wang X, Zhao B (2021) Guillain-Barr \u0301e syndrome in patients treated with immune checkpoint inhibitors. J Neurol 268:2169\u20132174","journal-title":"J Neurol"},{"key":"8422_CR95","first-page":"107","volume":"28","author":"AS Patel","year":"2019","unstructured":"Patel AS, Snook RJ, Sehdev A (2019) Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. Discov Med 28:107\u2013111","journal-title":"Discov Med"},{"key":"8422_CR96","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2340\/00015555-2548","volume":"97","author":"R Schneiderbauer","year":"2017","unstructured":"Schneiderbauer R, Schneiderbauer M, Wick W, Enk AH, Haenssle HA, Hassel JC (2017) PD-1 antibody-induced Guillain-Barr \u0301e syndrome in a patient with metastatic melanoma. Acta Derm Venereol 97:395\u2013396","journal-title":"Acta Derm Venereol"},{"key":"8422_CR97","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","volume":"24","author":"GGA Van Lieverloo","year":"2019","unstructured":"Van Lieverloo GGA, Wieske L, Verhamme C et al (2019) Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 24:187\u2013194","journal-title":"J Peripher Nerv Syst"},{"key":"8422_CR98","first-page":"e16539","volume":"19","author":"AM Afzali","year":"2024","unstructured":"Afzali AM, Vosko M, Reinhardt N, Zinevych I et al (2024) Serum neurofilament light chain predicts disease severity in axonal variants of acute immune neuropathies: A retrospective monocentric cohort study. Eur J Neurol 19:e16539","journal-title":"Eur J Neurol"},{"key":"8422_CR99","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13311-019-00716-5","volume":"16","author":"A Grimm","year":"2019","unstructured":"Grimm A, Oertl H, Auffenberg E et al (2019) Differentiation between Guillain\u2013Barr\u00e9 syndrome and acute-onset chronic inflammatory demyelinating polyradiculoneuritis\u2014a prospective follow-up study using ultrasound and neurophysiological measurements. Neurotherapeutics 16:838\u2013847","journal-title":"Neurotherapeutics"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08422-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08422-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08422-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T01:02:20Z","timestamp":1764896540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08422-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["8422"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08422-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct the presentation of Table 1.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no financial or other conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}